CN116077592A - 一种有益菌眼部护理组合物及包含该组合物的眼部护理品 - Google Patents
一种有益菌眼部护理组合物及包含该组合物的眼部护理品 Download PDFInfo
- Publication number
- CN116077592A CN116077592A CN202211413154.4A CN202211413154A CN116077592A CN 116077592 A CN116077592 A CN 116077592A CN 202211413154 A CN202211413154 A CN 202211413154A CN 116077592 A CN116077592 A CN 116077592A
- Authority
- CN
- China
- Prior art keywords
- eye care
- beneficial bacteria
- care composition
- eye
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 241000894006 Bacteria Species 0.000 title claims abstract description 39
- 230000009286 beneficial effect Effects 0.000 title claims abstract description 39
- 239000000047 product Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000000855 fermentation Methods 0.000 claims description 17
- 230000004151 fermentation Effects 0.000 claims description 17
- 241000186660 Lactobacillus Species 0.000 claims description 16
- 229940039696 lactobacillus Drugs 0.000 claims description 16
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 16
- 235000007164 Oryza sativa Nutrition 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 235000009566 rice Nutrition 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 8
- 229960003080 taurine Drugs 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 235000020712 soy bean extract Nutrition 0.000 claims description 7
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 6
- 229940058567 american elderberry extract Drugs 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 238000004945 emulsification Methods 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 3
- 229960005305 adenosine Drugs 0.000 claims description 3
- YVBGRQLITPHVOP-UHFFFAOYSA-L disodium;[hydroxy-[hydroxy(oxido)phosphoryl]oxyphosphoryl] hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)(=O)OP(O)([O-])=O YVBGRQLITPHVOP-UHFFFAOYSA-L 0.000 claims description 3
- 240000001972 Gardenia jasminoides Species 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 210000001508 eye Anatomy 0.000 abstract description 62
- 230000000694 effects Effects 0.000 abstract description 10
- 208000003464 asthenopia Diseases 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000004438 eyesight Effects 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 230000003020 moisturizing effect Effects 0.000 abstract description 2
- 208000005494 xerophthalmia Diseases 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 19
- 241000209094 Oryza Species 0.000 description 11
- 241000157835 Gardenia Species 0.000 description 7
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000003142 Sambucus nigra Nutrition 0.000 description 2
- 240000006028 Sambucus nigra Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- YLYJXNTZVUEFJZ-UHFFFAOYSA-N 3beta-Acetoxy-4alpha-methylergosta-8,24(28)-dien Natural products C1=CC(OC)=CC=C1C1=COC2=CC(OC3C(C(O)C(O)C(CO)O3)O)=C(OC)C=C2C1=O YLYJXNTZVUEFJZ-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004444 near reflex Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000036977 tonic contraction Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种有益菌眼部护理组合物及包含该组合物的眼部护理品，所述有益菌眼部护理组合物按照以下质量份数进行配比：乳酸杆菌/大米发酵产物0.5％‑50.0％、乳酸杆菌/大豆提取物发酵产物滤液1.0％‑20.0％、西洋接骨木果提取物0.1％‑5.0％、塔希提栀子花提取物0.1％‑5.0％、牛磺酸0.5％‑20.0％和三磷酸腺苷二钠0.5％‑5.0％，本发明一种有益菌眼部护理组合物及包含该组合物的眼部护理品，有益菌发酵产物配伍适用于眼部的天然中草药成分及药用成分，能有效的缓解眼部疲劳，促进眼部的血液循环，改善视力，同时防治干眼病、红血丝、红肿等多种眼部问题；本发明组合物还具有较强的深层补水、保湿润肤、舒缓敏感、抗衰老等功效，有效预防眼部皮肤老化、黑眼圈等眼周。
Description
技术领域
本发明涉及一种有益菌眼部护理组合物，特别涉及一种有益菌眼部护理组合物及包含该组合物的眼部护理品，属于有益菌眼部护理技术领域。
背景技术
现今，由于生活节奏快，随着电视、电脑、手机等电子产品的普及，以及办公一族的工作性质使然，越来越多人每天需要长时间接触电子产品的显示屏，使用计算机工作、娱乐，以及电视、手机的普及，导致眼部疲劳的加剧，诱发视疲劳。主要表现为眼睛和眉弓部胀痛、视物模糊、流泪、畏光、干涩等现象，给人们的学习、工作带来很大的影响；而长时间看书和长时间使用电脑、看电视，以及电脑、电视产生的放射线，眼睛的危害表现如：导致眼睛干涩疼痛，疲劳视力下降。
现代光环境下长期工作和学习所致的眼部红肿等不适症状也越来越普遍，青少年近视眼的患病率也在逐年升高，并有向低龄化、高度数发展的趋势。除了注意休息和加强营养外，药物辅助护理眼部也是一个很有效的方法，目前眼部护理药水种类繁多，如参天制药santen FX neo眼药水、珍视明等产品，但所起的效果比较短暂，需要反复使用，久而久之容易患上药物依赖症等。
此外，现代生活方式、眼部化妆等更是带给了眼部皮肤更多的伤害和负担，都使得人们的眼部皮肤变得更为脆弱敏感，从而更容易产生黑眼圈、细纹、松弛等一系列问题。市场上的眼部护理产品很难达到深层次的调节作用，效果慢，难以实现护肤、护眼的全面性和综合性的功效，且较多产品存在各种副作用，对眼部皮肤或眼睛造成更多的伤害。
发明内容
本发明的目的在于提供一种有益菌眼部护理组合物及包含该组合物的眼部护理品，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：一种有益菌眼部护理组合物及包含该组合物的眼部护理品，所述有益菌眼部护理组合物按照以下质量份数进行配比：
作为本发明的一种优选技术方案，所述有益菌眼部护理组合物按照以下质量份数进行配比：
作为本发明的一种优选技术方案，所述有益菌眼部护理组合物按照以下质量份数进行配比：
作为本发明的一种优选技术方案，所述有益菌眼部护理组合物按照以下质量份数进行配比：
作为本发明的一种优选技术方案，所述眼部护理品为液体状、啫喱状、乳液状或膏霜状。
作为本发明的一种优选技术方案，所述有益菌眼部护理组合物的制备方法步骤如下：
步骤一：首相按照质量份数称取以下乳酸杆菌/大米发酵产物0.5％-50.0％、乳酸杆菌/大豆提取物发酵产物滤液1.0％-20.0％、西洋接骨木果提取物0.1％-5.0％、塔希提栀子花提取物0.1％-5.0％、牛磺酸0.5％-20.0％和三磷酸腺苷二钠0.5％-5.0％；
步骤二：将油相原料进行混合，加热到75摄氏度－85摄氏度制成油相，再将水相成分混合均匀加热到75摄氏度－85摄氏度制成水相；
步骤三：将油相和水相都加入真空均质器中进行乳化，冷却到45摄氏度即可灌装成品。
与现有技术相比，本发明的有益效果是：本发明一种有益菌眼部护理组合物及包含该组合物的眼部护理品：
1、本发明的目的之一在于提供一种有益菌眼部护理组合物，有益菌发酵产物配伍适用于眼部的天然中草药成分及药用成分，能有效的缓解眼部疲劳，促进眼部的血液循环，改善视力，同时防治干眼病、红血丝、红肿等多种眼部问题；本发明组合物还具有较强的深层补水、保湿润肤、舒缓敏感、抗衰老等功效，有效预防眼部皮肤老化、黑眼圈等眼周问题。
2、本发明的目的之二在于提供一种包含上述有益菌眼部护理组合物的眼部护理品，可根据不同剂型使用不同的组合，方便、快捷，实现对眼睛和眼部皮肤的护理。
具体实施方式
对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
本发明提供了一种有益菌眼部护理组合物及包含该组合物的眼部护理品：
乳酸杆菌/大米发酵产物：能降低毛细血管脆性，提高肌肤未梢血管循环机能作用，防止肌肤皲裂并改善肌肤色泽，使肌肤绽放自然润白亮泽。大米发酵滤液还含有水解大米蛋白，是大米中特有的成分，对肌肤具有很高的渗透性，能维持细胞的柔软和湿润，有效保持肌肤表面水分，能在短时间里让角质水分充盈，使弹力纤维及胶原蛋白处在充满水分的环境中使肌肤更滋润更具弹性。乳酸杆菌/大米发酵产物，还含有稻糠甾醇，能促进肌肤新陈代谢、抑制肌肤，可舒缓日晒红斑，防止肌肤老化，减缓肌肤敏感概率。
乳酸杆菌/大豆提取物发酵产物滤液：乳酸菌代谢物，富含氨基酸、维他命、矿物元素及醣类黏液质，具有防护，舒缓，保湿，修复和美白效果。
西洋接骨木(SAMBUCUS NIGRA)果提取物：富含十一烯酸及类黄酮化合物，可提供抗炎、抗氧化及抗微生物等作用。
塔希提栀子(GARDENIA TAHITENSIS)花提取物：含黄酮类栀子素、果胶、鞣质、藏红花素等，有镇静、降压，抑菌、致泻、镇痛、抗炎，舒缓，加速软组织的愈合等作用。
牛磺酸：是一种内源性氨基酸，广泛分布于动物组织细胞内。具有保护视网膜、调节晶体渗透压和抗氧化等重要作用；牛磺酸有维护许多细胞，特别是血细胞抗氧化活性，使组织免受氧化基与自由基的损伤；提高细胞免疫吞噬功能，促进免疫球蛋白的生成的作用；具有赋活肌肤细胞的能力，可源源不断地提供年轻肌肤快速与持久的能量补充与多重保护，同时也具有提高肌肤免疫力，抵抗外界环境对肌肤的侵袭的功效。
三磷酸腺苷二钠是辅酶类药物，它是核苷酸衍生物，参与体内脂肪、蛋白质、糖、核酸以及核苷酸的代谢，三磷酸腺苷二钠还能够穿透血脑脊液屏障，能提高神经细胞膜性结构的稳定性和重建能力，促进神经突起的再生长。三磷酸腺苷能扩张末梢血管、促进血液循环，改善局部营养，促进水肿和渗出物的吸收，提高视神经和视网膜的作用；解除由眼睛长期的长时间做近反射三联运动，眼部肌群强直性收缩而导致的眼外肌、眼内虹膜睫状体(即前葡萄膜)和晶状体的同时水肿。
实施例一：所述有益菌眼部护理组合物按照以下质量份数进行配比：
进一步地，所述眼部护理品为液体状、啫喱状、乳液状或膏霜状。
更进一步地，所述有益菌眼部护理组合物的制备方法步骤如下：
步骤一：首相按照质量份数称取以下乳酸杆菌/大米发酵产物0.5％-50.0％、乳酸杆菌/大豆提取物发酵产物滤液1.0％-20.0％、西洋接骨木果提取物0.1％-5.0％、塔希提栀子花提取物0.1％-5.0％、牛磺酸0.5％-20.0％和三磷酸腺苷二钠0.5％-5.0％；
步骤二：将油相原料进行混合，加热到75摄氏度－85摄氏度制成油相，再将水相成分混合均匀加热到75摄氏度－85摄氏度制成水相；
步骤三：将油相和水相都加入真空均质器中进行乳化，冷却到45摄氏度即可灌装成品
实施例二：所述有益菌眼部护理组合物按照以下质量份数进行配比：
进一步地，所述眼部护理品为液体状、啫喱状、乳液状或膏霜状。
更进一步地，所述有益菌眼部护理组合物的制备方法步骤如下：
步骤一：首相按照质量份数称取以下乳酸杆菌/大米发酵产物1.5％-15.0％、乳酸杆菌/大豆提取物发酵产物滤液1.5％-5.0％、西洋接骨木果提取物0.1％-2.0％、塔希提栀子花提取物0.1％-2.0％、牛磺酸0.5％-2.0％和三磷酸腺苷二钠0.5％-2.0％；
步骤二：将油相原料进行混合，加热到75摄氏度－85摄氏度制成油相，再将水相成分混合均匀加热到75摄氏度－85摄氏度制成水相；
步骤三：将油相和水相都加入真空均质器中进行乳化，冷却到45摄氏度即可灌装成品
实施例三：所述有益菌眼部护理组合物按照以下质量份数进行配比：
进一步地，所述眼部护理品为液体状、啫喱状、乳液状或膏霜状。
更进一步地，所述有益菌眼部护理组合物的制备方法步骤如下：
步骤一：首相按照质量份数称取以下乳酸杆菌/大米发酵产物1.0％-20.0％、乳酸杆菌/大豆提取物发酵产物滤液1.0％-10.0％、西洋接骨木果提取物0.1％-1.5％、塔希提栀子花提取物0.5％-3.0％、牛磺酸0.5％-3.0％和三磷酸腺苷二钠0.5％-3.0％；
步骤二：将油相原料进行混合，加热到75摄氏度－85摄氏度制成油相，再将水相成分混合均匀加热到75摄氏度－85摄氏度制成水相；
步骤三：将油相和水相都加入真空均质器中进行乳化，冷却到45摄氏度即可灌装成品
实施例四：所述有益菌眼部护理组合物按照以下质量份数进行配比：
进一步地，所述眼部护理品为液体状、啫喱状、乳液状或膏霜状。
更进一步地，所述有益菌眼部护理组合物的制备方法步骤如下：
步骤一：首相按照质量份数称取以下乳酸杆菌/大米发酵产物2.0％-10.0％、乳酸杆菌/大豆提取物发酵产物滤液1.0％-8.0％、西洋接骨木果提取物0.1％-1.0％、塔希提栀子花提取物0.1％-1.5％、牛磺酸0.5％-2.0％和三磷酸腺苷二钠0.5％-2.0％；
步骤二：将油相原料进行混合，加热到75摄氏度－85摄氏度制成油相，再将水相成分混合均匀加热到75摄氏度－85摄氏度制成水相；
步骤三：将油相和水相都加入真空均质器中进行乳化，冷却到45摄氏度即可灌装成品。
尽管已经示出和描述了本发明的实施例，对于本领域的普通技术人员而言，可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由所附权利要求及其等同物限定。
Claims (6)
1.一种有益菌眼部护理组合物及包含该组合物的眼部护理品，其特征在于，所述有益菌眼部护理组合物按照以下质量份数进行配比：
2.根据权利要求1所述的一种有益菌眼部护理组合物及包含该组合物的眼部护理品，其特征在于：所述有益菌眼部护理组合物按照以下质量份数进行配比：
3.根据权利要求1所述的一种有益菌眼部护理组合物及包含该组合物的眼部护理品，其特征在于：所述有益菌眼部护理组合物按照以下质量份数进行配比：
4.根据权利要求1所述的一种有益菌眼部护理组合物及包含该组合物的眼部护理品，其特征在于：所述有益菌眼部护理组合物按照以下质量份数进行配比：
5.根据权利要求1所述的一种有益菌眼部护理组合物及包含该组合物的眼部护理品，其特征在于：所述眼部护理品为液体状、啫喱状、乳液状或膏霜状。
6.根据权利要求1所述的一种有益菌眼部护理组合物及包含该组合物的眼部护理品，其特征在于：所述有益菌眼部护理组合物的制备方法步骤如下：
步骤一：首相按照质量份数称取以下乳酸杆菌/大米发酵产物0.5％-50.0％、乳酸杆菌/大豆提取物发酵产物滤液1.0％-20.0％、西洋接骨木果提取物0.1％-5.0％、塔希提栀子花提取物0.1％-5.0％、牛磺酸0.5％-20.0％和三磷酸腺苷二钠0.5％-5.0％；
步骤二：将油相原料进行混合，加热到75摄氏度－85摄氏度制成油相，再将水相成分混合均匀加热到75摄氏度－85摄氏度制成水相；
步骤三：将油相和水相都加入真空均质器中进行乳化，冷却到45摄氏度即可灌装成品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211413154.4A CN116077592A (zh) | 2022-11-11 | 2022-11-11 | 一种有益菌眼部护理组合物及包含该组合物的眼部护理品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211413154.4A CN116077592A (zh) | 2022-11-11 | 2022-11-11 | 一种有益菌眼部护理组合物及包含该组合物的眼部护理品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116077592A true CN116077592A (zh) | 2023-05-09 |
Family
ID=86185692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211413154.4A Pending CN116077592A (zh) | 2022-11-11 | 2022-11-11 | 一种有益菌眼部护理组合物及包含该组合物的眼部护理品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116077592A (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127441A (zh) * | 2014-08-19 | 2014-11-05 | 宁夏瑞视眼科研究所 | 抗眼疲劳的滴眼液及其制备方法 |
| CN105147590A (zh) * | 2015-10-19 | 2015-12-16 | 广州科玛生物科技有限公司 | 一种抗皱眼霜及其制备方法 |
| CN110731941A (zh) * | 2018-07-02 | 2020-01-31 | 中山市泛华精细化学品有限公司 | 一种有益菌护肤的化妆品 |
| CN112006949A (zh) * | 2020-08-23 | 2020-12-01 | 博雅(广州)生物科技研究院有限公司 | 眼部修护组合物及其应用 |
| CN114146075A (zh) * | 2020-11-16 | 2022-03-08 | 裴丽林 | 一种治疗近视的牛磺酸外用药及其制备方法与应用 |
| CN114569546A (zh) * | 2020-11-16 | 2022-06-03 | 裴丽林 | 一种防治近视的三磷酸腺苷二钠外用药及其制备方法与应用 |
-
2022
- 2022-11-11 CN CN202211413154.4A patent/CN116077592A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127441A (zh) * | 2014-08-19 | 2014-11-05 | 宁夏瑞视眼科研究所 | 抗眼疲劳的滴眼液及其制备方法 |
| CN105147590A (zh) * | 2015-10-19 | 2015-12-16 | 广州科玛生物科技有限公司 | 一种抗皱眼霜及其制备方法 |
| CN110731941A (zh) * | 2018-07-02 | 2020-01-31 | 中山市泛华精细化学品有限公司 | 一种有益菌护肤的化妆品 |
| CN112006949A (zh) * | 2020-08-23 | 2020-12-01 | 博雅(广州)生物科技研究院有限公司 | 眼部修护组合物及其应用 |
| CN114146075A (zh) * | 2020-11-16 | 2022-03-08 | 裴丽林 | 一种治疗近视的牛磺酸外用药及其制备方法与应用 |
| CN114569546A (zh) * | 2020-11-16 | 2022-06-03 | 裴丽林 | 一种防治近视的三磷酸腺苷二钠外用药及其制备方法与应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105687055B (zh) | 一种眼部修护精华液及其制备方法 | |
| CN109620748B (zh) | 一种抗皱精华液及其制备方法 | |
| CN106309349B (zh) | 一种去黑眼圈及淡化细纹的组合物及其制备方法和应用 | |
| CN110772463B (zh) | 眼部肌肤修复组合物及其制备方法和应用 | |
| CN109602655A (zh) | 一种具有抗皱、去黑眼圈、去眼袋作用的组合物及其制备方法和应用 | |
| CN105395412A (zh) | 一种补水面膜 | |
| CN106420482A (zh) | 一种肌能赋活水光精华液 | |
| CN113693962A (zh) | 一种含纤连蛋白的多重蛋白修复组合物及其制备方法 | |
| CN111150686A (zh) | 一种肌初赋活多肽-角鲨烷鲜活按摩眼霜 | |
| US20220152429A1 (en) | Skincare system | |
| CN108888539A (zh) | 有机护肤基质及其制备方法和应用及有机化妆品 | |
| CN110787082A (zh) | 一种眼部细胞修复组合物及包含该组合物的眼部护理品 | |
| CN114028277A (zh) | 一种具有舒缓修复敏感肌肤的安肤膏 | |
| CN109602654A (zh) | 一种具有眼部护理功能的组合物及其制备方法和应用 | |
| CN113143798A (zh) | 一种茶油面霜及其制备方法 | |
| CN113133957A (zh) | 一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法 | |
| CN116077592A (zh) | 一种有益菌眼部护理组合物及包含该组合物的眼部护理品 | |
| CN113730330B (zh) | 一种具有祛黑眼圈功效的眼霜组合物及其制备方法 | |
| CN112999124B (zh) | 一种护眼喷雾及其制备方法 | |
| CN108721162A (zh) | 一种沉香平滑精华乳及其制备方法 | |
| CN108542829A (zh) | 一种植物保湿防晒霜及其制备方法 | |
| CN109481323A (zh) | 一种芦荟原汁保湿油及其制备方法 | |
| CN113827511A (zh) | 一种抗光损伤植物籽油透明微乳组合物及其制备方法 | |
| CN100372523C (zh) | 快速吸收的护肤组合物 | |
| CN111840199A (zh) | 一种蜂蜜面膜及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |